1524-1525 / 2063
Predictive biomarkers for cetuximab in HNSCC?
•
p16 and HPV are not predictive for outcomes of cetuximab-
containing treatment regimens in patients with
locoregionally advanced or recurrent/metastatic HNSCC
(despite their prognostic value)
Bonner J Oncologist 2017;22:811